Take Control of Your Cancer
Integrating the Best of Alternative and Conventional Treatments
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Audible会員プラン 無料体験
-
ナレーター:
-
Mike Chamberlain
このコンテンツについて
Cancer rates continue to skyrocket, and the overall survival rate for stage IV cancer patients in the United States is a grim 2.1 percent. Clearly, the extensive use of expensive - sometimes ineffective - toxins in conventional oncology protocols is a failing strategy. Even the few survivors of these harsh slash-and-burn treatments can have a dismal quality of life, suffering with ailments such as nerve damage, heart muscle disease, and liver and kidney failure. And unfortunately, many conventional doctors discourage patients from exploring alternative treatment options.
A featured doctor in Suzanne Somers’ bestselling cancer book Knockout, forty-year oncology veteran James W. Forsythe, MD, HMD, offers a more cost-effective, personalized, and compassionate alternative to traditional cancer treatment. Dr. Forsythe’s integrative approach has yielded an astonishing 46 percent positive response rate in a five-hundred-patient study.
In Take Control of Your Cancer, you will find information on all stages of cancer, including the warning signs of cancer, how to pinpoint the causes of cancer and to avoid its recurrence, preventive measures such as a healthy diet and regular exercise, an overview of how to choose what drugs and supplements to use, how to take charge of your cancer treatment and maintain a positive attitude, and the successful case studies of forty of Dr. Forsythe’s stage IV cancer patients.
While Dr. Forsythe offers his patients conventional and alternative therapies on their own, as well as an integrative option, Take Control of Your Cancer encourages cancer patients and their families to explore their treatment options and look for doctors who personalize treatment for optimal outcomes.
©2012 James W. Forsythe, MD, HMD (P)2012 Blackstone Audio, Inc.